Zylox-Tonbridge Medical Technology Co Ltd
HKEX:2190

Watchlist Manager
Zylox-Tonbridge Medical Technology Co Ltd Logo
Zylox-Tonbridge Medical Technology Co Ltd
HKEX:2190
Watchlist
Price: 18.58 HKD -2.93% Market Closed
Market Cap: 6B HKD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+11%
Revenue
Forecast
+10%
Operating Income
Forecast
+30%
Net Income
Forecast
+46%

Wall Street
Price Targets

Price Targets Summary
Zylox-Tonbridge Medical Technology Co Ltd

Wall Street analysts forecast Zylox-Tonbridge Medical Technology Co Ltd stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Zylox-Tonbridge Medical Technology Co Ltd is 19.18 HKD with a low forecast of 18.79 HKD and a high forecast of 19.95 HKD.

Lowest Forecast
Wall Street Target
18.79 HKD
1% Upside
Average Forecast
Wall Street Target
19.18 HKD
3% Upside
Highest Forecast
Wall Street Target
19.95 HKD
7% Upside
Lowest
Price Target
18.79 HKD
1% Upside
Average
Price Target
19.18 HKD
3% Upside
Highest
Price Target
19.95 HKD
7% Upside
Zylox-Tonbridge Medical Technology Co Ltd Competitors:
Price Targets
COH
Cochlear Ltd
12% Upside
L
2291
Lepu Scientech Medical Technology Shanghai Co Ltd
16% Downside
L
LUCD
Lucid Diagnostics Inc
188% Upside
R
228670
Ray Co Ltd
3% Downside
COH
Cochlear Ltd
12% Upside
L
2291
Lepu Scientech Medical Technology Shanghai Co Ltd
16% Downside
L
LUCD
Lucid Diagnostics Inc
188% Upside
R
228670
Ray Co Ltd
3% Downside
O
226400
Osteonic Co Ltd
36% Upside
DCTH
Delcath Systems Inc
90% Upside
EW
Edwards Lifesciences Corp
7% Upside
STMN
Straumann Holding AG
36% Upside

Revenue
Forecast

Revenue Estimate
Zylox-Tonbridge Medical Technology Co Ltd

For the last 4 years the compound annual growth rate for Zylox-Tonbridge Medical Technology Co Ltd's revenue is 131%. The projected CAGR for the next 2 years is 47%.

131%
Past Growth
47%
Estimated Growth
Estimates Accuracy
0%
Average Beat
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Zylox-Tonbridge Medical Technology Co Ltd

The compound annual growth rate of Zylox-Tonbridge Medical Technology Co Ltd's operating income for the next 2 years is 131%.

N/A
Past Growth
131%
Estimated Growth
Estimates Accuracy
22%
Average Beat
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Zylox-Tonbridge Medical Technology Co Ltd

The compound annual growth rate of Zylox-Tonbridge Medical Technology Co Ltd's net income for the next 3 years is 46%.

N/A
Past Growth
46%
Estimated Growth
Estimates Accuracy
19%
Average Beat
What are analyst estimates?

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is Zylox-Tonbridge Medical Technology Co Ltd's stock price target?
Price Target
19.18 HKD

According to Wall Street analysts, the average 1-year price target for Zylox-Tonbridge Medical Technology Co Ltd is 19.18 HKD with a low forecast of 18.79 HKD and a high forecast of 19.95 HKD.

What is Zylox-Tonbridge Medical Technology Co Ltd's Revenue forecast?
Projected CAGR
47%

For the last 4 years the compound annual growth rate for Zylox-Tonbridge Medical Technology Co Ltd's revenue is 131%. The projected CAGR for the next 2 years is 47%.

What is Zylox-Tonbridge Medical Technology Co Ltd's Operating Income forecast?
Projected CAGR
131%

The compound annual growth rate of Zylox-Tonbridge Medical Technology Co Ltd's operating income for the next 2 years is 131%.

What is Zylox-Tonbridge Medical Technology Co Ltd's Net Income forecast?
Projected CAGR
46%

The compound annual growth rate of Zylox-Tonbridge Medical Technology Co Ltd's net income for the next 3 years is 46%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 248,800+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.